Moving the motivation meter

November 08, 2018

Two novel drugs kickstart motivation in rats suffering from apathy and a lack of oomph, UConn researchers reported at the Society for Neuroscience conference in San Diego on Nov. 5.

Apathy steals the excitement from life. It's a feeling of being fatigued, uninterested, and emotionally flat. People who suffer from apathy find it hard to exert effort, and life can seem tremendously difficult. One of the primary symptoms of depression, it's also a side effect of certain medications. It can also be caused by inflammation from an infection or chronic disease such as multiple sclerosis.

Apathy and lack of motivation are hard to treat. Many medications that help with other symptoms of depression don't help much with them.

But now, UConn behavioral neuroscientist John Salamone and graduate student Renee Rotolo have found that two new drugs can restore normal behavior in rats who lack motivation, pointing the way to potential treatments.

Salamone and Rotolo's rats were not naturally lacking motivation; the researchers induced it with a drug that reduces dopamine signals in the brain. Dopamine affects many things, including mood, motivation, and movement. It works by affecting brain cells when it is released into the synapses (the spaces between the cells). Certain medicines used to treat movement disorders restrict the amount of dopamine available to fill the synapses in the brain. This does calm spastic movements, but it can also cause apathy, fatigue, and low exertion of effort.

Salamone, Rotolo, and other lab members showed that rats given the drug that reduced dopamine were much less likely to work for preferred morsels of food. But when these rats were then given one of the experimental drugs, they regained their motivation to work for the treat.

Both of the experimental drugs Rotolo and Salamone tested stimulate a build up of dopamine in the synapse. They do this by inhibiting the protein that normally clears dopamine away. Other drugs, such as cocaine and amphetamines, work in a similar fashion, but their onset is much faster and the effects more extreme.

"You wouldn't want to give a person with depression cocaine over and over again. They'd crash. These [experimental] drugs provide a long, slow, mild increase in dopamine," which would be much more likely to be therapeutic, Salamone says. They also, hopefully, may have a lower potential for abuse.

One of the new drugs was developed by the British pharmaceutical company Chronos Therapeutics; the other by an Austrian medicinal chemist Gert Lubec from the Universities of Vienna and Salzburg. Lubec has developed a large family of related drug candidates to increase motivation, all related to modafinil. Modafinil, a drug developed initially to enhance wakefulness, also helps people concentrate on a task and engage with it more. Neuroscientists believe it does this by blocking the inactivation of dopamine from synapses in the brain responsible for attention and focus. Lubec intentionally changed the chemical structure of the drug, which made it even more selective for actions on dopamine.

The next step in the research will be to test these other, related drugs in the series and see if they have similar effects, and identify which one works best to mitigate apathy and fatigue. Salamone's team also intends to test whether the compounds really do have less potential for abuse than more rapidly acting drugs.
-end-


University of Connecticut

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.